Download PDF
Thromb Haemost 1978; 40(01): 075-082
DOI: 10.1055/s-0038-1648636
Original Article
Schattauer GmbH Stuttgart

The Effect of ICI 55,897 and Clofibrate on Platelet Function and Other Tests Abnormal in Atherosclerosis

J R O’Brien
The Portsmouth and South East Hampshire District Pathology Service, Central Laboratory, St. Mary’s Hospital, Portsmouth, Hants., England
,
M D Etherington
The Portsmouth and South East Hampshire District Pathology Service, Central Laboratory, St. Mary’s Hospital, Portsmouth, Hants., England
,
Sandra Jamieson
The Portsmouth and South East Hampshire District Pathology Service, Central Laboratory, St. Mary’s Hospital, Portsmouth, Hants., England
,
Janet Sussex
The Portsmouth and South East Hampshire District Pathology Service, Central Laboratory, St. Mary’s Hospital, Portsmouth, Hants., England
,
R D Shuttleworth
The Portsmouth and South East Hampshire District Pathology Service, Central Laboratory, St. Mary’s Hospital, Portsmouth, Hants., England
› Author Affiliations
Further Information

Publication History

Received 19 August 1977

Accepted 26 January 1978

Publication Date:
12 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

There is considerable evidence that the quantity or quality of plasma lipids influences platelet function tests, and clofibrate reduces high plasma lipids and alters some platelet tests. Clofibrate was accordingly given to patients with vascular disease who were at risk of thrombosis. The heparin thrombin clotting time (HTCT), initially short and thus possibly reflecting increased activation, was regularly returned to normal after about a month’s delay. The fibrinogen was also normalized but the initially abnormal anti-thrombic activity became more abnormal. ICI 55,897, an analogue of clofibrate, also normalized the HTCT and the fibrinogen and had no adverse effect on the anti-thrombin levels. This compound has no effect on plasma lipids. If it can be shown that the correction of abnormal tests conveys clinical benefit these findings suggest that ICI 55,897 might clinically be more beneficial than clofibrate. However, direct comparison of clofibrate and ICI 55,897 suggests that clofibrate is more effective in normalizing the HTCT. The mechanisms underlying these drug-induced changes are unknown but they cannot be directly related to lipid changes.

 

  • References

  • 1 Carvalho A, Colman RW, Lees RS. 1974; Clofibrate reversal of platelet hyper-sensitivity in β-hyperlipoproteinaemia. Circulation 50: 570
    CrossrefPubMedSearch in Google Scholar
  • 2 Cella G, Russo R. 1977; Heparin neutralizing activity (HNA) and anti-thrombin III in coronary artery disease. Thrombosis and Haemostasis 38: 696
    Thieme ConnectPubMedSearch in Google Scholar
  • 3 Chakrabarti B, Fearnley GR, Evans JF. 1968; Effects of clofibrate on fibrinolysis, platelet stickiness, plasma-fibrinogen and serum cholesterol. Lancet 2: 1007
    PubMedSearch in Google Scholar
  • 4 Connerty HV, Briggs AR, Eaton EH. 1961; Simplified determination of the lipid components of blood serum. Clinical Chemistry 7: 37
    PubMedSearch in Google Scholar
  • 5 Cotton RC. 1972; The action of Atromid-S on lipids and other plasma factors which may be involved in arterial thrombosis. Acta Cardiologica Suppl (Suppl. 15) 163
    PubMedSearch in Google Scholar
  • 6 Dana B, Ellman L, Carvalho A, Daggett WM, Hutter AM. 1976; Plasma heparin neutralizing activity in coronary artery disease. American Journal of Cardiology 38: 9
    CrossrefPubMedSearch in Google Scholar
  • 7 Dudea C, Kifor I, Kotay E. 1974; Effects of clofibrate on platelets in atherosclerosis: modification of their count, content of lipids and of the activity of platelet factor 3 and platelet factor 4. Thrombosis Research Suppl (Suppl. 01) 4: 77
    PubMedSearch in Google Scholar
  • 8 Kifor I, Dudea C, Kotay E. 1974; Effects of lipid phagocytation on platelet degranulation and on coagulation. Thrombosis Research Suppl (Suppl. 01) 4: 83
    CrossrefPubMedSearch in Google Scholar
  • 9 Nordøy A, Strøm E, Gjesdal K. 1974; The effect of alimentary lipaemia and primary hypertriglyceridaemia on platelets in man. Scandinavian Journal of Haematology 12: 329
    PubMedSearch in Google Scholar
  • 10 O’Brien JR, Etherington MD. 1977; Effect of heparin and warfarin on anti-thrombin III. Lancet 2: 1232
    PubMedSearch in Google Scholar
  • 11 O’Brien JR, Etherington MD, Jamieson S. 1976; a Acute platelet changes after large meals of saturated and unsaturated fats. Lancet 1: 878
    PubMedSearch in Google Scholar
  • 12 O’Brien JR, Etherington MD, Jamieson S, Lawford P, Lincoln SV, Alkjaersig NJ. 1975; Blood changes in atherosclerosis and long after myocardial infarction and venous thrombosis. Thrombosis et Diathesis Haemorrhagica 34: 483
    PubMedSearch in Google Scholar
  • 13 O’Brien JR, Etherington MD, Jamieson S, Vergroesen AJ, Ten Hoor F. 1976; b Effects of a diet of polyunsaturated fats on some platelet function tests. Lancet 2: 995
    PubMedSearch in Google Scholar
  • 14 O’Brien JR, Heywood JB. 1966; A comparison of platelet stickiness tests during an Atromid trial. Thrombosis et Diathesis Haemorrhagica 16: 768
    PubMedSearch in Google Scholar
  • 15 Renaud S. 1977. Thromboses éxperimentales et functions plaquettaires: application de ces resultats a l’homme. Thesis - Université Claude Bernard; Lyon, France:
    Search in Google Scholar
  • 16 Rice EW, Muesse DE R. 1972; Clinical nephelometry 1. New, accurate heat-precipitation nephelometric method for rapid determination of plasma fibrinogen. Clinical Chemistry 18: 73
    PubMedSearch in Google Scholar
  • 17 Steele P, Battock D, Genton E. 1975; Effects of clofibrate and sulphinpyrazone on platelet survival time in coronary artery disease. Circulation 52: 473
    CrossrefPubMedSearch in Google Scholar
  • 18 Stone MC, Thorp JM. 1966; A new technique for the investigation of the low-density lipoproteins in health and disease. Clinica Chimica Acta 14: 812
    CrossrefPubMedSearch in Google Scholar
  • 19 Stone MC, Thorp JM, Wain JS. 1975; Experimental and clinical evaluation of two Atromid-S analogues in relation to their differential modes of action. Advances in Experimental Medicine and Biology 63: 151
    PubMedSearch in Google Scholar